Provinces and Territories are Overdue for an Update in Healthcare Funding Policies

The mission of the Real-World Evidence and Outcomes-Based Agreements Working Group is to advance the opportunity for the use of real-world evidence (RWE) and outcomes-based agreements (OBAs) to the benefit of all stakeholders in the Canadian healthcare system.Established in 2019, the working group conducts research on RWE and OBAs to support shared learnings on OBA implementation for Canadian stakeholders, including HTA, the pCPA, payers, patients, physicians, academics, and industry.The scope of the working group includes all therapeutic areas and both public and private payer markets.The working group values inclusion, knowledge sharing and collaboration, and invites input and participation from all interested parties.20Sense chairs the working group.2022 members include AbbVie, AstraZeneca, Bayer, BioScript Solutions, Janssen, and Pfizer.For further information, resources, and past publications from the RWE & OBA Working Group, please consult https://www.20sense.ca/obas.